The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results, Practical Considerations for Personalized Cancer Care

For patients with advanced non-small cell lung cancer (NSCLC), tissue samples are typically small biopsies. These samples undergo standard of care evaluation for >10 biomarkers to identify targeted, personalized therapies. If only single-gene tests are ordered, it is unlikely all biomarkers will be successfully tested. Furthermore, the patient may not be able to get a second biopsy for comprehensive testing. Ordering single-gene tests before comprehensive profiling creates longer wait times for results, which can be problematic for selecting optimal treatment.

From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates

Labcorp Oncology's Medical Affairs Team explore the evolving role of HER2 overexpression in various solid tumors and discuss how advancements in Antibody Drug Conjugates, particularly T-DXd, are transforming treatment strategies in solid malignancies. They also highlight the challenges in HER2 testing across pan-solid tumors and the potential of NGS and AI algorithms to enhance diagnostic accuracy.

Graphical Summary: A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors

Key TakeawaysOur GIA calls aligned well with reference populations of inferred ancestries, were highly concordant with SIRE (95%), and could expand upon SIRE by detecting ancestries missing appropriate SIRE groups.Accurate GIA provides essential data to support ancestryaware biomarker research, promote the inclusion of underrepresented groups in clinical studies, and enhance diverse representation in precision clinical trials.

American Association for Cancer Research® (AACR) Annual Meeting 2025

American Association for Cancer Research® (AACR) Annual Meeting 2025